🚀 VC round data is live in beta, check it out!
Livzon Pharmaceutical Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Livzon Pharmaceutical Group and similar public comparables like Zealand Pharma, Hualan Biological Engineering, Ligand Pharmaceuticals, Ajanta Pharma and more.
Livzon Pharmaceutical Group Overview
About Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug addresses serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in the PRC which is pharmaceutical manufacturing.
Founded
1992
HQ
Employees
9.1K
Website
Sectors
Financials (LTM)
EV
$3B
Livzon Pharmaceutical Group Financials
Livzon Pharmaceutical Group reported last 12-month revenue of $2B and EBITDA of $483M.
In the same LTM period, Livzon Pharmaceutical Group generated $1B in gross profit, $483M in EBITDA, and $322M in net income.
Revenue (LTM)
Livzon Pharmaceutical Group P&L
In the most recent fiscal year, Livzon Pharmaceutical Group reported revenue of $2B and EBITDA of $503M.
Livzon Pharmaceutical Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $483M | XXX | $503M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $322M | XXX | $299M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Livzon Pharmaceutical Group Stock Performance
Livzon Pharmaceutical Group has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Livzon Pharmaceutical Group's stock price is $4.54.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 0.0% | XXX | XXX | XXX | $0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLivzon Pharmaceutical Group Valuation Multiples
Livzon Pharmaceutical Group trades at 1.7x EV/Revenue multiple, and 6.2x EV/EBITDA.
EV / Revenue (LTM)
Livzon Pharmaceutical Group Financial Valuation Multiples
As of March 7, 2026, Livzon Pharmaceutical Group has market cap of $4B and EV of $3B.
Equity research analysts estimate Livzon Pharmaceutical Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Livzon Pharmaceutical Group has a P/E ratio of 12.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 6.2x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBIT | 7.3x | XXX | 7.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | 2.7x | XXX | XXX | XXX |
| P/E | 12.5x | XXX | 13.5x | XXX | XXX | XXX |
| EV/FCF | 9.9x | XXX | 8.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Livzon Pharmaceutical Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Livzon Pharmaceutical Group Margins & Growth Rates
Livzon Pharmaceutical Group's revenue in the last 12 month grew by 4%.
Livzon Pharmaceutical Group's revenue per employee in the last FY averaged $0.2M.
Livzon Pharmaceutical Group's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Livzon Pharmaceutical Group's rule of X is 38% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Livzon Pharmaceutical Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | (5%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Livzon Pharmaceutical Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zealand Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Hualan Biological Engineering | XXX | XXX | XXX | XXX | XXX | XXX |
| Ligand Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Ajanta Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Centessa Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Livzon Pharmaceutical Group M&A Activity
Livzon Pharmaceutical Group acquired XXX companies to date.
Last acquisition by Livzon Pharmaceutical Group was on XXXXXXXX, XXXXX. Livzon Pharmaceutical Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Livzon Pharmaceutical Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLivzon Pharmaceutical Group Investment Activity
Livzon Pharmaceutical Group invested in XXX companies to date.
Livzon Pharmaceutical Group made its latest investment on XXXXXXXX, XXXXX. Livzon Pharmaceutical Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Livzon Pharmaceutical Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Livzon Pharmaceutical Group
| When was Livzon Pharmaceutical Group founded? | Livzon Pharmaceutical Group was founded in 1992. |
| Where is Livzon Pharmaceutical Group headquartered? | Livzon Pharmaceutical Group is headquartered in China. |
| How many employees does Livzon Pharmaceutical Group have? | As of today, Livzon Pharmaceutical Group has over 9K employees. |
| Is Livzon Pharmaceutical Group publicly listed? | Yes, Livzon Pharmaceutical Group is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Livzon Pharmaceutical Group? | Livzon Pharmaceutical Group trades under 000513 ticker. |
| When did Livzon Pharmaceutical Group go public? | Livzon Pharmaceutical Group went public in 1993. |
| Who are competitors of Livzon Pharmaceutical Group? | Livzon Pharmaceutical Group main competitors are Zealand Pharma, Hualan Biological Engineering, Ligand Pharmaceuticals, Ajanta Pharma. |
| What is the current market cap of Livzon Pharmaceutical Group? | Livzon Pharmaceutical Group's current market cap is $4B. |
| What is the current revenue of Livzon Pharmaceutical Group? | Livzon Pharmaceutical Group's last 12 months revenue is $2B. |
| What is the current revenue growth of Livzon Pharmaceutical Group? | Livzon Pharmaceutical Group revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Livzon Pharmaceutical Group? | Current revenue multiple of Livzon Pharmaceutical Group is 1.7x. |
| Is Livzon Pharmaceutical Group profitable? | Yes, Livzon Pharmaceutical Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Livzon Pharmaceutical Group? | Livzon Pharmaceutical Group's last 12 months EBITDA is $483M. |
| What is Livzon Pharmaceutical Group's EBITDA margin? | Livzon Pharmaceutical Group's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Livzon Pharmaceutical Group? | Current EBITDA multiple of Livzon Pharmaceutical Group is 6.2x. |
| What is the current FCF of Livzon Pharmaceutical Group? | Livzon Pharmaceutical Group's last 12 months FCF is $304M. |
| What is Livzon Pharmaceutical Group's FCF margin? | Livzon Pharmaceutical Group's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Livzon Pharmaceutical Group? | Current FCF multiple of Livzon Pharmaceutical Group is 9.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.